Table III.

 Titration Effect: Change in Blood Pressure—All Participants Entering the Open‐Label Extension Period With Dosage Change in Study Medication

	OM 40/AML 5/HCTZ 12.5 mg to OM 40/AML 5/HCTZ 25 mg	OM 40/AML 5/HCTZ 12.5 mg to OM 40/AML 10/HCTZ 12.5 mg	OM 40/AML 5/HCTZ 25 mg to OM 40/AML 10/HCTZ 25 mg	OM 40/AML 10/HCTZ 12.5 mg to OM 40/AML 10/HCTZ 25 mg
No.a	604	639	360	383
Change in SeDBP, mean (SD)	−2.9 (8.3)	−4.4 (8.7)	−5.7 (9.4)	−5.0 (9.1)
Change in SeSBP, mean (SD)	−5.9 (13.6)	−6.8 (13.3)	−9.9 (15.0)	−10.2 (13.8)

Abbreviations: AML, amlodipine besylate; BP, blood pressure; HCTZ, hydrochlorothiazide; OM, olmesartan medoxomil; SD, standard deviation; SeDBP, seated diastolic blood pressure; SeSBP, seated systolic blood pressure. Titration effect was calculated as BP measurement at last visit on the new dose regimen minus BP measurement at last visit of the previous dose regimen. ^aNumber of titration events. Six participants had duplicate titration events from OM 40/AML 5/HCTZ 12.5 mg to OM 40/AML 10/HCTZ 12.5 mg. Two participants had duplicate titration events from OM 40/AML 10/HCTZ 12.5 mg to OM 40/AML 10/HCTZ 25 mg.